Key result
Rosuvastatin plus ticagrelor cuts MACE ~71% versus ticagrelor alone in PCI patients.
Why the study?
Previous studies reported conflicting results on the efficacy of rosuvastatin plus ticagrelor versus ticagrelor monotherapy in patients undergoing PCI.
Does rosuvastatin plus ticagrelor reduce major adverse cardiovascular events and improve cardiac function compared with ticagrelor alone in patients undergoing percutaneous coronary intervention?
Meta-Analysis (n=850)
Does rosuvastatin plus ticagrelor reduce major adverse cardiovascular events and improve cardiac function compared with ticagrelor alone in patients undergoing percutaneous coronary intervention?
In patients undergoing PCI, the addition of rosuvastatin to ticagrelor significantly reduced the risk of MACE and improved echocardiographic parameters of cardiac function compared to ticagrelor alone.
Supports adding rosuvastatin to ticagrelor post-PCI to cut MACE and improve LV function; reinforces pooled RCT and cohort data.
Several previous studies have reported that rosuvastatin plus ticagrelor is superior to ticagrelor monotherapy in patients receiving percutaneous coronary intervention (PCI); several others, however, dispute this. The present meta-analysis summarized relevant studies, aiming to comprehensively explore the efficacy of rosuvastatin plus ticagrelor vs. ticagrelor monotherapy in patients receiving PCI. Published studies comparing the efficacy between rosuvastatin plus ticagrelor and ticagrelor alone among patients receiving PCI were searched in the CNKI, Wanfang, CQVIP, EMBASE, Cochrane and PubMed databases until January 2023. The present meta-analysis included 3 cohort studies and 4 randomized controlled trials with 426 patients receiving rosuvastatin plus ticagrelor and 424 patients receiving ticagrelor monotherapy. Rosuvastatin plus ticagrelor decreased the occurrence of major adverse cardiovascular events (MACE) compared with ticagrelor [relative risk (RR), 0.29; 95% confidence interval (CI), 0.18-0.47]. Subgroup analysis revealed similar findings in studies with a follow-up of <6 months (RR, 0.24; 95% CI, 0.13-0.47) and ≥6 months (RR, 0.36; 95% CI, 0.18-0.70), as well as in studies using 10 mg rosuvastatin (RR, 0.27; 95% CI, 0.15-0.50) and 20 mg rosuvastatin (RR, 0.33; 95% CI, 0.16-0.69). In addition, rosuvastatin plus ticagrelor decreased the left ventricular (LV) end-systolic diameter [mean difference (MD), -0.71; 95% CI, -(1.36-0.07)], LV end-diastolic diameter [MD, -1.17; 95% CI, -(1.91-0.43)] and N-terminal pro-B-type natriuretic peptide [MD, -2.97; 95% CI, -(4.55-1.38)], and increased the LV ejection fraction (MD, 0.99; 95% CI, 0.74-1.25). In conclusion, rosuvastatin plus ticagrelor was shown to decrease the risk of MACE and elevate cardiac function compared with ticagrelor monotherapy in patients receiving PCI.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2023) conducted a meta-analysis in Patients undergoing percutaneous coronary intervention (PCI) (n=850). Rosuvastatin plus ticagrelor vs. Ticagrelor monotherapy was evaluated on Major adverse cardiovascular events (MACE) (RR 0.29, 95% CI 0.18-0.47, p=<0.001). Rosuvastatin plus ticagrelor significantly decreased the risk of major adverse cardiovascular events (RR 0.29) compared with ticagrelor alone in patients undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: